Boji Medical Technology Co., Ltd.
Boji Medical Technology Co., Ltd.(Boji for short, stock code: 300404), founded in 2002 and listed in Shenzhen GEM in 2015.
Boji Medical Technology Co., Ltd.
Boji Medical Technology Co., Ltd. (Boji for short, stock code: 300404), founded in 2002 and listed in Shenzhen GEM in 2015.
Boji Medical Technology Co., Ltd.
Boji Medical Technology Co., Ltd. (Boji for short, stock code: 300404), founded in 2002 and listed in Shenzhen GEM in 2015.
Boji Medical Technology Co., Ltd.
Boji Medical Technology Co., Ltd.(Boji for short, stock code: 300404), founded in 2002 and listed in Shenzhen GEM in 2015.
Boji Medical Technology Co., Ltd.
Boji Medical Technology Co., Ltd.(Boji for short, stock code: 300404), founded in 2002 and listed in Shenzhen GEM in 2015.
Boji Medical Technology Co., Ltd.
Boji Medical Technology Co., Ltd. (Boji for short, stock code: 300404), founded in 2002 and listed in Shenzhen GEM in 2015.
Boji Medical Technology Co., Ltd.
Boji Medical Technology Co., Ltd.(Boji for short, stock code: 300404), founded in 2002 and listed in Shenzhen GEM in 2015.
"One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
"One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
"One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
"One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
"One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
"One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
"One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
"One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
"One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
"One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
"One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
"One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
"One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
"One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
Boji Medical Technology Co., Ltd.
Boji Medical Technology Co., Ltd.(Boji for short, stock code: 300404), founded in 2002 and listed in Shenzhen GEM in 2015.
Boji Medical Technology Co., Ltd.
Boji Medical Technology Co., Ltd.(Boji for short, stock code: 300404), founded in 2002 and listed in Shenzhen GEM in 2015.
service content
Video
  • Company News
  • Industry News
  • Regulations and Policies
  • Bay Area New Drug Exchange 2022 Spring Dinner Salon was successfully held in Guangzhou
    2022/02/27
    Recently, the Bay Area New Drug Exchange 2022 Spring Dinner Salon, hosted by Guangdong Biomedical Innovation Technology Association Bay Area New Drug Exchange and organized by Boji Pharmaceutical, was held at Guangzhou Nikko Hotel. The salon attracted nearly 60 biopharmaceutical industry leaders from Guangdong, Hong Kong and Macau Bay Area to participate in it.The theme of this salon is "New drug R&D strategy under the new situation and discussion on the similarities and differences of new drug review in China and the United States", which aims to promote the process of biopharmaceutical R&D innovation in the Greater Bay Area under the new situation, grasp the favorable policies of biopharmaceutical industry in the "Guangdong, Hong Kong and Macao Greater Bay Area", and discuss the industry The aim is to promote the process of biopharmaceutical R&D innovation in the Greater Bay Area under the new situation, grasp the favorable policies of the biopharmaceutical industry in the Greater Bay Area, and discuss the innovative development path of the industry. In particular, the recent setback of domestic PD-1s first FDA clearance, the new drug R&D and US-China review and regulation topics discussed in this conference are quite realistic considerations.
  • Boji Pharmaceuticals signed a collaboration agreement with a client on Phase III clinical trial of a new class 1 drug!
    2022/03/04
    Recently, the signing ceremony for the phase III clinical trial of "Ipiutide Nasal Drops" for the treatment of allergic rhinitis between Boji Pharmaceutical and Wuhan Yicheng Biotechnology Co. The signing ceremony marked that the Class 1 new drug "Ipiutide Nasal Drops" is about to enter the critical phase III clinical study stage for the application of new drug certificate."It is the first formulation developed for various nasal inflammatory diseases with Eptifibatide as API.Ltd. and Boji Pharma will provide Phase III clinical studies and subsequent drug registration services for the project.
Boji pharmaceutical
  • Founding Time
    Founded in 2002
  • Industry
    Contract Research Organization
  • Market Status
    Leading domestic CRO enterprises; International and well-known companies
  • Number Of Employees
    More than 700 pharmaceutical researchers
  • Development History

    After 18 years of development, Boji Pharmaceutical has ranked among China's CRO companies in terms of technical strength, service quality, service scope, operating income, team building.


  • Company Culture

    Strategic goals: Consolidate domestic leadership, achieve international leadership and build acentury-old brand.

    Business philosophy: Think for customers, serve customers, make progress together with customers.


Cooperation Agency

Our company always adheres to the concept of "professional, honest, enterprising and harmonious". After nearly a decade of clinical research in new drugs, our company has achieved rapid development.


  • Phone:400-0020-628
  • Address:Clinical Center:7th Floor, Building A, Vanke Cloud Plaza, 1933 Huaguan Road, Tianhe District, Guangzhou / Laboratory Address:No.62,Nanxiang One Road,Huangpu Disrict,Guangzhou
Copyright © Boji Medical Technology Co., Ltd. All Rights Reserved 粤ICP备13039920号 (粤)—非经营性—2020-0084 Powered by vancheer
Copyright © Boji Medical Technology Co., Ltd. All Rights Reserved 粤ICP备13039920号 (粤)—非经营性—2020-0084 Powered by vancheer